Assessment of IMPACT III Emotional and Social Functioning Domain Scores in Adalimumab-Treated Pediatric Patients With Crohn's Disease

被引：0
|
作者：
Grant, Amy
Otley, Anthony R.
Escher, Johanna
Hyams, Jeffrey S.
Maa, Jen-Fue
Alperovich, Gabriela
Lazar, Andreas
Robinson, Anne M.
Wang, Anthony
Eichner, Samantha
机构：
来源：
GASTROENTEROLOGY | 2016年 / 150卷 / 04期
关键词：
D O I：
10.1016/S0016-5085(16)33397-2
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Tu2005
引用
收藏
页码：S1003 / S1004
页数：2
相关论文
共 50 条
  • [41] Patterns and predictors of dosage increase in patients treated with Adalimumab for Crohn's Disease in the United States
    Loftus, E., Jr.
    Pan, X.
    Zurawski, P.
    Chao, J.
    Mulani, P.
    INFLAMMATORY BOWEL DISEASES, 2009, 15 (12) : S24 - S24
  • [42] Adalimumab-induced lupus erythematosus in Crohn's disease patients previously treated with infliximab
    不详
    GUT, 2008, 57 (04) : 559 - 559
  • [43] Crohn's disease patients treated with adalimumab benefit from co-treatment with immunomodulators
    van der Valk, Mirthe E.
    van Oijen, Martijn G. H.
    Ammerlaan, Marije
    Siersema, Peter D.
    Oldenburg, Bas
    GUT, 2012, 61 (02) : 324 - 325
  • [44] Autoregressive cross-lagged models of IMPACT-III and Pediatric Crohn's Disease Activity indexes during one year infliximab therapy in pediatric patients with Crohn's disease
    Szabo, Doloresz
    Koekoenyei, Gyongyi
    Arato, Andras
    Dezsofi, Antal
    Molnar, Kriszta
    Mueller, Katalin Eszter
    Lakatos, Peter Laszlo
    Papp, Maria
    Lovasz, Barbara D.
    Golovics, Petra A.
    Cseh, Aron
    Veres, Gabor
    JOURNAL OF CROHNS & COLITIS, 2014, 8 (08): : 747 - 755
  • [45] Effect of Adalimumab on Clinical Laboratory Parameters in Pediatric Crohn's Disease Patients From IMAgINE 1
    Hyams, Jeffrey S.
    Rosh, Joel R.
    Markowitz, James
    Kierkus, Jaroslaw
    Dubinsky, Marla
    Turner, Dan
    Faubion, William A.
    Eichner, Samantha
    Lazar, Andreas
    Li, Yao
    Thakkar, Roopal
    GASTROENTEROLOGY, 2015, 148 (04) : S638 - S639
  • [46] Efficacy and safety of adalimumab in pediatric patients with Crohn’s disease: A systematic review and meta-analysis
    Bin Chen
    Zhuan Zou
    Xiaoyan Zhang
    Dongqiong Xiao
    Xihong Li
    European Journal of Clinical Pharmacology, 2024, 80 : 395 - 407
  • [47] Efficacy and safety of adalimumab in pediatric patients with Crohn's disease: A systematic review and meta-analysis
    Chen, Bin
    Zou, Zhuan
    Zhang, Xiaoyan
    Xiao, Dongqiong
    Li, Xihong
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2024, 80 (03) : 395 - 407
  • [48] Impact of Adalimumab in the Prevention of Postoperative Recurrences of Crohn's Disease in High-Risk Patients
    Aguas, Mariam
    Bastida, Guillermo
    Cerrillo, Elena
    Beltran, Belen
    Iborra, Marisa
    Munoz, Fernando
    Barrio, Jesus
    Riestra, Sabino
    Nos, Pilar
    GASTROENTEROLOGY, 2012, 142 (05) : S384 - S384
  • [49] Incidence of Bowel Surgery in a Cohort of Crohn's Disease Patients Treated with Infliximab or Adalimumab in Lazio, Italy
    Di Domenicantonio, Riccardo
    Agabiti, Nera
    Cascini, Silvia
    Trotta, Francesco
    Addis, Antonio
    Kohn, Anna
    Davoli, Marina
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2016, 25 : 519 - 519
  • [50] Does co-treatment with immunosuppressors improve outcome in patients with Crohn's disease treated with adalimumab?
    Reenaers, C.
    Louis, E.
    Belaiche, J.
    Seidel, L.
    Keshav, S.
    Travis, S.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2012, 36 (11-12) : 1040 - 1048
12345